Ocean Biomedical, INC. (OCEA) — SEC Filings

Q: What are the key financial highlights for Ocean Biomedical, INC.?

Key financial highlights for Ocean Biomedical, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Ocean Biomedical, INC.?

Key executives at Ocean Biomedical, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Ocean Biomedical, INC. stock?

Risk factors for Ocean Biomedical, INC. (OCEA) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Ocean Biomedical, INC.?

Forward-looking statements and predictions from Ocean Biomedical, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Ocean Biomedical, INC.. Recent 8-K filing on Aug 5, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Ocean Biomedical, INC. on SEC EDGAR

Overview

Ocean Biomedical, INC. (OCEA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Aug 5, 2025: Ocean Biomedical, Inc. filed an 8-K on August 5, 2025, reporting events as of July 31, 2025. The filing indicates a potential delisting or failure to meet listing standards, a departure of directors or officers, and the appointment of new officers. It also mentions compensatory arrangements for cert

Sentiment Summary

Across 43 filings, the sentiment breakdown is: 1 bullish, 14 bearish, 28 neutral. The dominant filing sentiment for Ocean Biomedical, INC. is neutral.

Filing Type Overview

Ocean Biomedical, INC. (OCEA) has filed 29 8-K, 3 10-Q, 1 10-K/A, 2 10-K, 1 10-Q/A, 6 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Aug 2025.

Filings by Year

2025 · 2024

Recent Filings (43)

Ocean Biomedical Faces Delisting Concerns, Officer Changes — 8-K · Aug 5, 2025 Risk: high
Ocean Biomedical, Inc. filed an 8-K on August 5, 2025, reporting events as of July 31, 2025. The filing indicates a potential delisting or failure to meet listi
Ocean Biomedical Faces Delisting Concerns — 8-K · Jul 23, 2025 Risk: high
Ocean Biomedical, Inc. filed an 8-K on July 23, 2025, reporting a notice of delisting or failure to satisfy continued listing rules as of July 17, 2025. The com
Ocean Biomedical Terminates Material Definitive Agreement — 8-K · Jul 16, 2025 Risk: medium
Ocean Biomedical, Inc. announced on July 10, 2025, the termination of a material definitive agreement. The company, formerly known as Aesther Healthcare Acquisi
Ocean Biomedical Terminates Material Definitive Agreement — 8-K · Jun 13, 2025 Risk: medium
Ocean Biomedical, Inc. announced on June 12, 2025, the termination of a material definitive agreement. The company, formerly known as Aesther Healthcare Acquisi
Ocean Biomedical Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
Ocean Biomedical, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Aesther Healthcare Acquisition Corp., is involved in
Ocean Biomedical Files 2024 Annual Report Amendment — 10-K/A · Apr 29, 2025 Risk: low
Ocean Biomedical, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The company, previously known as Aesther He
Ocean Biomedical Faces Delisting Concerns — 8-K · Apr 23, 2025 Risk: high
Ocean Biomedical, Inc. filed an 8-K on April 23, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The filing also covers th
Ocean Biomedical Files 2024 10-K — 10-K · Apr 8, 2025 Risk: medium
Ocean Biomedical, Inc. filed its 2024 10-K on April 8, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Aesther Healt
Ocean Biomedical Files 8-K on Shareholder Vote Matters — 8-K · Apr 1, 2025 Risk: low
Ocean Biomedical, Inc. filed an 8-K on April 1, 2025, reporting on matters submitted to a vote of its security holders as of March 28, 2025. The filing details
Ocean Biomedical to Acquire Algaeventures — 8-K · Mar 26, 2025 Risk: medium
Ocean Biomedical, Inc. announced on March 26, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of Algaeventures, Inc. The
Ocean Biomedical Faces Delisting Concerns — 8-K · Mar 20, 2025 Risk: high
Ocean Biomedical, Inc. filed an 8-K on March 20, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing in
Ocean Biomedical Announces Board and Officer Changes — 8-K · Mar 10, 2025 Risk: medium
Ocean Biomedical, Inc. announced on March 4, 2025, changes in its board of directors and officer appointments. Specifically, the company elected new directors a
Ocean Biomedical Files 8-K on Equity Sales & Bylaw Changes — 8-K · Feb 26, 2025 Risk: medium
Ocean Biomedical, Inc. filed an 8-K on February 26, 2025, reporting unregistered sales of equity securities and amendments to its articles of incorporation or b
Ocean Biomedical Files 8-K for Bylaw Amendments & Fiscal Year Change — 8-K · Feb 21, 2025 Risk: low
Ocean Biomedical, Inc. filed an 8-K on February 21, 2025, reporting amendments to its Articles of Incorporation or Bylaws, and a change in its fiscal year. The
Ocean Biomedical Reports Unregistered Equity Sales — 8-K · Feb 12, 2025 Risk: medium
Ocean Biomedical, Inc. filed an 8-K on February 12, 2025, reporting unregistered sales of equity securities and other events that occurred on February 11, 2025.
Ocean Biomedical Faces Nasdaq Delisting Warning — 8-K · Jan 15, 2025 Risk: high
Ocean Biomedical, Inc. received a notice on January 7, 2025, regarding its failure to meet the continued listing requirements of the Nasdaq Capital Market. The
Ocean Biomedical Files Q3 2024 10-Q — 10-Q · Jan 13, 2025 Risk: medium
Ocean Biomedical, Inc. filed its quarterly report for the period ending September 30, 2024. The company, formerly known as Aesther Healthcare Acquisition Corp.,
Ocean Biomedical Files Q1 2024 10-Q — 10-Q · Dec 23, 2024 Risk: medium
Ocean Biomedical, Inc. filed its 10-Q for the period ending March 31, 2024. The company, formerly known as Aesther Healthcare Acquisition Corp., is involved in
Ocean Biomedical Changes Auditors — 8-K · Dec 17, 2024 Risk: low
Ocean Biomedical, Inc. announced on December 17, 2024, a change in its certifying accountant. The company has dismissed its previous independent registered publ
Ocean Biomedical Faces Delisting Concerns — 8-K · Dec 11, 2024 Risk: high
Ocean Biomedical, Inc. filed an 8-K on December 11, 2024, to report a notice of delisting or failure to satisfy continued listing rules. The company's common st
Ocean Biomedical Faces Delisting Concerns — 8-K · Dec 9, 2024 Risk: high
Ocean Biomedical, Inc. filed an 8-K on December 9, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing
Ocean Biomedical Changes Auditors to Marcum LLP — 8-K · Dec 6, 2024 Risk: medium
Ocean Biomedical, Inc. filed an 8-K on December 6, 2024, reporting a change in its certifying accountant. The company has appointed Marcum LLP as its new indepe
Ocean Biomedical Files 2023 10-K — 10-K · Nov 25, 2024 Risk: medium
Ocean Biomedical, Inc. filed its 10-K for the fiscal year ending December 31, 2023. The company, formerly known as Aesther Healthcare Acquisition Corp. until a
Ocean Biomedical Faces Delisting Concerns — 8-K · Nov 22, 2024 Risk: high
Ocean Biomedical, Inc. filed an 8-K on November 22, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The filing indicates p
Ocean Biomedical Appoints New CMO, Elects Director — 8-K · Oct 29, 2024 Risk: medium
Ocean Biomedical, Inc. announced on October 23, 2024, the appointment of Dr. Jonathan Roth as Chief Medical Officer and the election of Dr. David Lee to its Boa
Ocean Biomedical Faces Delisting Notice — 8-K · Oct 22, 2024 Risk: high
Ocean Biomedical, Inc. filed an 8-K on October 22, 2024, reporting a notice of delisting or failure to satisfy continued listing rules as of October 16, 2024. T
Ocean Biomedical Enters Material Definitive Agreement — 8-K · Oct 17, 2024 Risk: medium
Ocean Biomedical, Inc. entered into a Material Definitive Agreement on October 11, 2024. The filing also includes financial statements and exhibits related to t
Ocean Biomedical Faces Delisting Concerns — 8-K · Aug 23, 2024 Risk: high
Ocean Biomedical, Inc. filed an 8-K on August 19, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is also prov
Ocean Biomedical Files 8-K: Material Agreement & Equity Sales — 8-K · Jul 23, 2024 Risk: medium
Ocean Biomedical, Inc. entered into a material definitive agreement on July 22, 2024, related to the creation of a direct financial obligation. The company also
Ocean Biomedical Faces Delisting Concerns — 8-K · May 30, 2024 Risk: high
Ocean Biomedical, Inc. filed an 8-K on May 22, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, previously kno
Ocean Biomedical Faces Delisting Concerns — 8-K · Apr 24, 2024 Risk: high
Ocean Biomedical, Inc. filed an 8-K on April 24, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing in
Ocean Biomedical, Inc. Files 10-Q/A Amendment — 10-Q/A · Apr 15, 2024 Risk:
Ocean Biomedical, Inc. (OCEA) filed a Amended Quarterly Report (10-Q/A) with the SEC on April 15, 2024. Ocean Biomedical, Inc. filed a 10-Q/A amendment on April
Ocean Biomedical Elects New Director — 8-K · Mar 8, 2024 Risk: low
Ocean Biomedical, Inc. announced on March 4, 2024, a change in its board of directors. Specifically, the company elected Dr. Jonathan Roth as a new director. Th
Ocean Biomedical Appoints New Director, Reports Officer Compensation — 8-K · Mar 4, 2024 Risk: medium
Ocean Biomedical, Inc. announced on January 30, 2024, a change in its board of directors. Specifically, the company reported the departure of Director Dr. Jonat
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G Filing — SC 13G · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
First Trust Amends Ocean Biomedical Stake, Ownership Update — SC 13G/A · Feb 12, 2024 Risk: low
First Trust Capital Management L.P. filed an amended Schedule 13G/A on February 12, 2024, updating its beneficial ownership in Ocean Biomedical, Inc. (formerly
Polar Asset Management Discloses 7.7% Stake in Ocean Biomedical — SC 13G/A · Feb 9, 2024 Risk: low
Polar Asset Management Partners Inc. filed an amended SC 13G/A on February 9, 2024, disclosing its beneficial ownership in Ocean Biomedical, Inc. As of December
Saba Capital Amends Ocean Biomedical Stake, Signals Continued Interest — SC 13G/A · Feb 7, 2024
Saba Capital Management, L.P. filed an amended Schedule 13G/A on February 7, 2024, indicating their ownership in Ocean Biomedical, Inc. (formerly Aesther Health
Weiss Asset Mgmt Amends Ocean Biomedical Stake — SC 13G/A · Jan 26, 2024
Weiss Asset Management LP, a Boston-based investment firm, filed an amended Schedule 13G/A on January 26, 2024, indicating a change in their beneficial ownershi
Ocean Biomedical (OCEA) to be Delisted from Nasdaq Jan 29 — 8-K · Jan 19, 2024
Ocean Biomedical, Inc. (OCEA) announced on January 17, 2024, that it received a delisting notice from The Nasdaq Stock Market LLC because its common stock and w
Ocean Biomedical Receives Nasdaq Delisting Notice for Non-Compliance — 8-K · Jan 17, 2024
Ocean Biomedical, Inc. (OCEA) announced on January 11, 2024, that it received a delisting notice from The Nasdaq Stock Market LLC. This notice indicates that th

Risk Profile

Risk Assessment: Of OCEA's 35 recent filings, 12 were flagged as high-risk, 16 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Key Executives

Dr. Jonathan Roth
Dr. David Lee
Dr. Jonathan S. Roth
Dr. David G. R. Smith

Industry Context

Ocean Biomedical, Inc. operates within the pharmaceutical preparations industry, focusing on the development and commercialization of pharmaceutical products.

Top Tags

delisting (14) · pharmaceuticals (7) · compliance (6) · listing-standards (5) · amendment (5) · financials (4) · institutional-ownership (4) · governance (3) · regulatory-filing (3) · 10-Q (3)

Key Numbers

SEC File Number: 001-40793 — Identifies the company's filing with the SEC.
IRS Employer Identification No.: 87-1309280 — Company's tax identification number.
Period End Date: 20250331 — The filing covers the financial period ending on this date.
Filing Date: 20250515 — The date the 10-Q was officially submitted to the SEC.
SIC Code: 2834 — Standard Industrial Classification for Pharmaceutical Preparations
Fiscal Year End: 2024-12-31 — Reporting period for the 10-K
IRS Number: 87-1309280 — Company's Employer Identification Number.
Reporting Period End Date: 20240930 — Indicates the end of the fiscal quarter for which financial information is reported.
Shares Beneficially Owned: 2,688,193 — This is the total number of common shares of Ocean Biomedical, Inc. held by Polar Asset Management Partners Inc. as of December 31, 2023.
Percent of Class: 7.7% — This represents the percentage of Ocean Biomedical, Inc.'s common stock owned by Polar Asset Management Partners Inc., indicating a significant stake.
Date of Event: 12/31/2023 — This is the date as of which the beneficial ownership percentage was calculated for this filing.

Forward-Looking Statements

{"claim":"Polar Asset Management Partners Inc. will likely maintain its significant stake in Ocean Biomedical, Inc. in the near term.","entity":"Polar Asset Management Partners Inc.","targetDate":"Q2 2024","confidence":"medium"}

Related Companies

OCEAN

Frequently Asked Questions

What are the latest SEC filings for Ocean Biomedical, INC. (OCEA)?

Ocean Biomedical, INC. has 43 recent SEC filings from Jan 2024 to Aug 2025, including 29 8-K, 6 SC 13G/A, 3 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of OCEA filings?

Across 43 filings, the sentiment breakdown is: 1 bullish, 14 bearish, 28 neutral. The dominant sentiment is neutral.

Where can I find Ocean Biomedical, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Ocean Biomedical, INC. (OCEA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Ocean Biomedical, INC.?

Financial highlights for Ocean Biomedical, INC. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for OCEA?

The investment thesis for OCEA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Ocean Biomedical, INC.?

Key executives identified across Ocean Biomedical, INC.'s filings include Dr. Jonathan Roth, Dr. David Lee, Dr. Jonathan S. Roth, Dr. David G. R. Smith.

What are the main risk factors for Ocean Biomedical, INC. stock?

Of OCEA's 35 assessed filings, 12 were flagged high-risk, 16 medium-risk, and 7 low-risk.

What are recent predictions and forward guidance from Ocean Biomedical, INC.?

Recent forward-looking statements from Ocean Biomedical, INC. include guidance on {"claim":"Polar Asset Management Partners Inc. will likely maintain its significant stake in Ocean Biomedical, Inc. in t.